Contributors
GEORGE P. CANELLOS, MD (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - May 3, 2024 Category: Cancer & Oncology Source Type: research
Contents
David H. Ilson (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - May 3, 2024 Category: Cancer & Oncology Source Type: research
Forthcoming Issues
Cancer Precursor Syndromes and their Detection (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - May 3, 2024 Category: Cancer & Oncology Source Type: research
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model
Patients with cytogenetically normal acute myeloid leukemia (CN-AML) may harbor prognostically relevant gene mutations and thus be categorized into one of the three 2022 European LeukemiaNet (ELN) genetic-risk... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - May 3, 2024 Category: Hematology Authors: Kellie J. Archer, Han Fu, Krzysztof Mr ózek, Deedra Nicolet, Alice S. Mims, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann, Klaus H. Metzeler, Tobias Herold and Ann-Kathrin Eisfeld Tags: Correspondence Source Type: research
Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians
T-cell redirecting therapies such as chimeric antigen receptor T-cells and bispecific antibodies, are emerging as a novel class of immunotherapeutic agents for treatment of relapsed refractory multiple myeloma (MM). Their use is associated with an increased risk of infectious adverse events, fostered by cytopenias, hypogammaglobulinemia and T-cell exhaustion. Multiple ongoing clinical trials and real-world studies are investigating safety of T-cell therapy, highlighting the need for strategies to prevent and monitor the risk of infection. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2024 Category: Hematology Authors: Tommaso Lupia, Lorenzo Cani, Sara Bringhen, Francesco Giuseppe De Rosa, Benedetto Bruno, Malgorzata Mikulska, Silvia Corcione, Roberto Mina Tags: Review Article Source Type: research
Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma
Anti-BCMA-directed chimeric antigen receptor (CAR) T cells are effective treatment for patients with refractory/relapsed multiple myeloma (RRMM). However, little is known about the impact of previous allogeneic hematopoietic stem cell transplantation (allo-HSCT) on lymphocyte collection for production of CAR T cells and subsequent treatment with CAR T cells. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2024 Category: Hematology Authors: Janine Kirchberg, Luise Fischer, Patrick Born, Franziska Brunner, Charlotte Morgner, Daniel F ürst, Simone Heyn, Enrica Bach, Mandy Brueckner, Madlen Jentzsch, Song-Yau Wang, Sebastian Böttcher, Georg-Nikolaus Franke, Hubert Schrezenmeier, Uwe Platzbeck Tags: Original Study Source Type: research
A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping
Blood Cancer Journal, Published online: 03 May 2024; doi:10.1038/s41408-024-01059-xA comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 3, 2024 Category: Hematology Authors: Ying S. Zou Melanie Klausner Jen Ghabrial Victoria Stinnett Patty Long Laura Morsberger Jaclyn B. Murry Katie Beierl Christopher D. Gocke Rena R. Xian Kevin H. Toomer Jing Christine Ye Robert Z. Orlowski Carol Ann Huff Syed Abbas Ali Philip H. Imus Christ Source Type: research
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
T-cell engagers (TCE) are cancer immunotherapies that have recently demonstrated meaningful benefit for patients with hematological malignancies and solid tumors. The anticipated widespread use of T cell engagers poses implementation challenges and highlights the need for guidance to anticipate, mitigate, and manage adverse events. By mobilizing T-cells directly at the contact of tumor cells, TCE mount an obligatory and immediate anti-tumor immune response that could result in diverse reactions and adverse events. (Source: European Journal of Cancer)
Source: European Journal of Cancer - May 3, 2024 Category: Cancer & Oncology Authors: Arthur G éraud, Thomas Hueso, Ariane Laparra, Naike Bige, Kaissa Ouali, Cécile Cauquil, Annabelle Stoclin, François-Xavier Danlos, Antoine Hollebecque, Vincent Ribrag, Anas Gazzah, Vincent Goldschmidt, Capucine Baldini, Steve Suzzoni, Rastislav Bahleda Tags: Review Source Type: research
Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients
Bone Marrow Transplantation, Published online: 03 May 2024; doi:10.1038/s41409-024-02295-2Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients (Source: Bone Marrow Transplantation)
Source: Bone Marrow Transplantation - May 3, 2024 Category: Hematology Authors: Philipp Berning Lina Kolloch Christian Reicherts Simon Call Julia Marx Matthias Floeth Eva Esseling Julian Ronnacker J örn Albring Christoph Schliemann Georg Lenz Matthias Stelljes Source Type: research
Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012 –2023)
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - May 3, 2024 Category: Allergy & Immunology Authors: Lele MiaoJuan ZhangWei XuQian QianGuochao ZhangQuan YuanYuetao LvHaiguo ZhangChaoyan ShenWei Wanga Department of Thyroid and Breast Surgery, Jining NO.1 People ’s Hospital, Jining, Chinab Department of Hematology, Jining NO.1 People’s Hospital, Jining Source Type: research
Ocimum gratissimum essential oil in the transport water of Brycon hilarii: implications at water quality, blood parameters and residues in tissue and plasma
This study aimed to assess the impact of Ocimum gratissimum L. essential oil (OGEO) on water quality, hematological parameters, and residue levels in the plasma, fillet, and liver of juvenile piraputanga (Brycon hilarii) during a two-hour transportation period. The fish were divided into plastic bags (4 L) and exposed to three different OGEO concentrations (10, 20, and 30 mg L-1), while a control group received no OGEO (three repetitions each). After the two-hour transportation, blood samples were collected, as well as portions of the fillet and liver for quantifying essential oil compounds, which were also measured in the...
Source: Braz J Biol - May 2, 2024 Category: Biology Authors: F C Oliveira A P Moreira A L Ferreira D C Costa C A L Cardoso F C M Chaves E C Chagas C M Campos Source Type: research
Anemia and Associated Factors among Public Elementary School Children in Asella Town, Southeast Ethiopia: A Facility-Based Cross-Sectional Study
CONCLUSION: Anemia among school-age children was found to be a mild public health problem. Uneducated mothers, intestinal parasite infections, and underweight children were found to be determinants of anemia among school-age children. Health professionals should provide health education for mothers about child-feeding practices and the consumption of dietary sources of iron.PMID:38694783 | PMC:PMC11062769 | DOI:10.1155/2024/1519382 (Source: Anemia)
Source: Anemia - May 2, 2024 Category: Hematology Authors: Ararso Hordofa Guye Kasim Hansa Kasahun Ketema Meseret Moroda Dame Banti Shambi Source Type: research
Red cell mass measurement is still useful for myeloproliferative neoplasms management. Comment to "Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes Myeloprolif ératifs"
Haematologica. 2024 May 2. doi: 10.3324/haematol.2024.285481. Online ahead of print.ABSTRACTNot available.PMID:38695122 | DOI:10.3324/haematol.2024.285481 (Source: Haematologica)
Source: Haematologica - May 2, 2024 Category: Hematology Authors: Nada Maaziz Fran çois Girodon Source Type: research
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN
Haematologica. 2024 May 2. doi: 10.3324/haematol.2023.283428. Online ahead of print.ABSTRACTEarly molecular response (EMR) at 3 months is predictive of improved overall survival (OS) and progression-free survival (PFS) in patients with chronic myeloid leukemia in the chronic phase (CML-CP). Although about one-third of patients treated with first-line imatinib do not achieve EMR, long-term OS and PFS are still observed in most patients. DASCERN (NCT01593254) is a prospective, phase IIb, randomized trial evaluating a switch to dasatinib in patients who have not achieved EMR after 3 months of treatment with first-line imatini...
Source: Haematologica - May 2, 2024 Category: Hematology Authors: Jorge E Cortes Qian Jiang Jianxiang Wang Jianyu Weng Huanling Zhu Xiaoli Liu Andreas Hochhaus Dong-Wook Kim Jerald Radich Michael Savona Patricia Martin-Regueira Oumar Sy Giuseppe Saglio Source Type: research
The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort
In conclusion, this first comparative study of early therapeutic response parameters showed that they are excellent indicators of TKI efficacy (BCR::ABL1 transcript reduction) and best responders. Conversely, they did not predict the achievement of the TKI discontinuation criteria and TFR maintenance, suggesting that other parameters are involved in TFR maintenance.PMID:38695126 | DOI:10.3324/haematol.2023.284860 (Source: Haematologica)
Source: Haematologica - May 2, 2024 Category: Hematology Authors: Sandrine Saugues C éline Lambert Elisabeth Daguenet Gabrielle Roth-Guepin Fran çoise Huguet Pascale Cony-Makhoul Hyacinthe Johnson Ansah Martine Escoffre-Barbe Ali Turhan Philippe Rousselot Andre ï Tchirkov Dalil Hamroun Eric Hermet Bruno Pereira Marc Source Type: research
